Immunotherapy With Myasthenia Gravis — or Neurological Autoimmunity

Rarely, and only after a joint oncology and neurology assessment. Myasthenia gravis sits in the highest-caution group in current immune-related toxicity guidance from ASCO, ESMO and NCCN. It is not written down as an absolute ban. In practice, checkpoint inhibitors are avoided in most people with generalised or active myasthenia gravis.

That is a harder answer than the one on our page about autoimmune disease in general, where the usual answer is yes with closer monitoring. Neurological autoimmunity is the exception, and it is worth understanding why rather than simply being told no.

The reason is anatomical, not statistical. Myasthenia gravis affects the junction between nerve and muscle, and the muscles it affects include the ones you use to swallow and to breathe. A flare of a joint or skin condition is unpleasant. A flare here can become a medical emergency within days.

This page explains the mechanism, the warning signs that matter, the narrow circumstances in which immunotherapy is still considered, and what should happen instead if it is ruled out.

If you are already on immunotherapy and have new weakness, drooping eyelids, double vision, difficulty swallowing or breathlessness, do not read on — contact your oncology team now, or go to the emergency department if it is severe or worsening. If you cannot reach your treating doctor, call 1800 202 8726.

Because of where the disease sits and how fast it can move. Myasthenia gravis weakens the signal between nerve and muscle. The muscles affected control the eyelids, eye movement, speech, chewing, swallowing and breathing. Releasing a brake on the immune system in that setting has somewhere serious to go.

There are two separate risks here, and they get confused constantly. The first is a worsening of the myasthenia you already have. At its most severe this is a myasthenic crisis — weakness of the breathing muscles needing ventilatory support in intensive care. The second is a new immune-related reaction that has nothing to do with your existing diagnosis.

That second risk is the one most patients have never had explained. Checkpoint inhibitors can cause new inflammation of muscle, of the nerve-muscle junction, and of the heart. These three frequently appear together as a single overlapping reaction, and it is among the most serious immune-related side effects described in the guideline literature. Having myasthenia gravis does not protect you from it.

Speed is the third reason. Most immune-related side effects give you some warning — a rash, a rising thyroid reading, a change in bowel habit over weeks. Neuromuscular and cardiac reactions can progress within days, and steroids do not always reverse them quickly enough. Escalation may need immunoglobulin or plasma exchange in a hospital with critical care on site.

There is a fourth consideration specific to this group. Many people with myasthenia gravis are already on steroids or steroid-sparing immunosuppressants. That baseline immunosuppression is itself part of the assessment, because reducing it to give immunotherapy a fair chance can destabilise the myasthenia that the medicines are holding steady.

An honest limitation: patients with neurological autoimmune disease were excluded from the registration trials, so the evidence is published case series and registries rather than randomised data. Anyone quoting you a confident percentage for your own situation is ahead of what is actually known.

General patterns at guidance level only. Your own team’s assessment of your case overrides anything in this table, in either direction. For the genuine stopping points across all of immunotherapy, see Who Should Not Have Immunotherapy at All?

If any of the signs below appear, contact your oncology team the same day, and go to the emergency department now if it is severe or getting worse. Say clearly that you are on immunotherapy and that you have myasthenia gravis. If you cannot reach your treating doctor, call 1800 202 8726. Do not manage any of these at home and do not wait for the next cycle.

Timings are general patterns reported in guideline literature, not a schedule your body has agreed to. Symptoms outside these windows still count. Tell every doctor you see — including in an emergency department — that you are on or have recently had immunotherapy, because the treatment for an immune-related reaction is different from the treatment for the same symptom in someone who is not.

Immunotherapy is given as day care at CION centres, and response assessment by PET-CT is coordinated at partner imaging centres. CION does not provide CAR-T or other cell therapies; those are referral pathways elsewhere.

Ask for the reason and the alternative plan together. Here, unlike most autoimmune situations, a no is often the correct answer — but you are still owed the reasoning. A properly made decision names your neurological diagnosis, its current activity, and what is being offered instead.

The difference matters. A reasoned no ends the uncertainty and lets you put your energy into the treatment that is actually right for you. An unexplained no leaves you searching, and searching is where people find clinics promising things that immunotherapy has never been shown to do for anyone.

If nobody has spoken to your neurologist, the assessment is not finished. If the alternative plan has not been named, the conversation is not finished either. Both are reasonable things to ask for, and most oncologists would rather you asked than quietly accepted an answer nobody had worked out.

For the wider picture of who this treatment is not for, Who Should Not Have Immunotherapy at All? sets out the genuine stopping points without softening them. If your autoimmune condition is not neurological, Can You Have Immunotherapy With an Autoimmune Disease? is the more relevant page — the answer there is usually much more open.

• Your neurologist’s most recent letter — the last consultation note usually shows how active the condition is better than any test.
• Your current medicine list with doses — especially steroids and steroid-sparing immunosuppressants. The dose matters as much as the name.
• A short crisis history — whether you have ever needed hospital admission or ventilation for your myasthenia, and when. Two lines is enough.
• Any breathing test results — and a recent ECG if you have one, so a baseline can be established without delay.
• Whether a thymus operation was ever done — and any thymic tumour reports, which change the discussion significantly.
• Your neurologist’s contact details — so the two teams can speak directly rather than relaying messages through you.

• If your autoimmune condition is not neurological, Can You Have Immunotherapy With an Autoimmune Disease? is the page that applies to you — and the answer there is usually far more open.
• For the genuine stopping points across the whole treatment, Who Should Not Have Immunotherapy at All? sets them out plainly.
• If a decision is close and you want to know which tests come first, Pre-Treatment Workup Before Starting Immunotherapy lists the baseline assessment.
• For how immunotherapy is delivered, monitored and followed up as day care, see Immunotherapy at CION Cancer Clinics.

General patient-education information only. Nothing here states or implies that immunotherapy is safe, suitable or unsuitable for you — that assessment is made by your treating medical oncologist together with the neurologist who manages your condition. Response-assessment PET-CT is coordinated at partner imaging centres.

Get the Eligibility Question Answered Properly

A medical oncologist, working with the neurologist who manages your myasthenia gravis, can tell you where you actually stand — and what the alternatives are.

This page is general patient-education information, not a substitute for the written assessment your own medical oncologist and neurologist give you for your specific case.